Completed PHASE3 NCT00465205

HSV-2 Suppression to Reduce HIV-1 Levels in HIV-1 Co-infected Persons

A Randomized,Double-Blind , Placebo-Controlled Crossover Trial of Antivirals for Suppression of HSV and HIV Shedding in HIV-1, HSV-2 Co-infected Persons

Sponsor: Asociación Civil Impacta Salud y Educación, Peru

Conditions HIV Infections Herpes Simplex Sexually Transmitted Diseases

Interventions Matching Placebo Valacyclovir

Updated 5 times since 2017 Last updated: Aug 21, 2013 Started: Jan 31, 2005 Primary completion: Dec 31, 2005 Completion: Dec 31, 2007

A PHASE3 clinical study on HIV Infections and Herpes Simplex, this trial is completed. The trial is conducted by Asociación Civil Impacta Salud y Educación, Peru and has accumulated 5 data snapshots since 2005. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jan 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Asociación Civil Impacta Salud y Educación, Peru
GlaxoSmithKline
University of Washington

Data source: University of Washington

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lima, Peru